Table 3 Individual echocardiographic cardiac parameters measured at baseline (T0), after 12 months of ERT (T1) and after 12 months of therapy with migalastat (T2).

From: Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data

ID

LVMI (g/m2)

IVSWT (mm)

LVPWT (mm)

LVEF (%)

E/A

 

T0

T1

T2

T0

T1

T2

T0

T1

T2

T0

T1

T2

T0

T1

T2

1

57

54.3

52.5

14

13

13

13

13

13

56

56

56

0.71

0.71

0.71

2

32.2

32.7

32.7

9

10

10

8

8

8

56

65

53

1.88

1.7

1.47

3

25

32.1

26

7

8

8

6

8

7

63

63

66

1.27

2.06

1.66

4

46

42.4

42.5

10

10

9

8

8

9

60

60

58

1.65

1.62

1.49

5

53

52

50

13

13

12

12

12

11

55

55

55

1

1.1

1

6

31.5

33.5

26.5

9

8

8

8

8

7

61

57

54

1.59

1.81

2.5

7

32.4

31

30

9

8

8

8

8

7

67

67

67

1.46

1.46

1.46

  1. E/A early to late diastolic transmitral flow velocity, IVSWT interventricular septum wall thickness, LVEF ejection fraction, LVMI left ventricular mass index, LVPWT left ventricular posterior wall thickness.
Back to article page